Effect of Guggul and Haritaki Churna in the Management of Diabetic Dyslipidemia

A Clinical Study to Evaluate the Efficacy of Guggul and Haritaki Churna in the Management of Diabetic Dyslipidemia

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/09/021286

Enrollment

Registered

2019-09-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E789- Disorder of lipoprotein metabolism, unspecified

Interventions

Intervention1: Cap Guggul and haritaki churna: Group-A sample size-20 Cap guggul 500mg bd and haritaki churna 3gm hs for a period of 8 weeks Control Intervention1: Tab Rosuvastatin 10mg: Group-B sampl

Eligibility

Inclusion criteria

Inclusion criteria: a)Patients willing for trial and ready to give written consent. b)Age- 20-70 years of either sex. c)Patients fulfilling the criteria of diagnosis.

Exclusion criteria

Exclusion criteria: a)Patients not willing for trial. b)Patients suffering from major systemic illness necessitating long term treatment (R.A., PTB, malignancy). c)Poorly controlled hypertensive patients(SBP>=160mm of Hg and/or DSB>=100mm of Hg). d)Patients with FBS >150mg/dl ; PPBS > 200mg/dl ; RBS > 250mg/dl. e)Patients having concomitant disorders like ischemic heart disease, congestive heart failure, acute renal failure, chronic renal failure etc. f)Patients below 20 years and above 70 years of age.

Design outcomes

Primary

Measure	Time frame
To Evaluate the Efficacy of trial drugs in the management of Diabetic DyslipidemiaTimepoint: 12months	—

Secondary

Measure	Time frame
To Assess the safety of the trial drugs in patients of Diabetic Dyslipidemia. Timepoint: 12months	—

Countries

India

Contacts

Public ContactDr Priyanka bhardwaj

Rajiv Gandhi Govt Post graduate Ayurvedic college

drvijaychaudhary@gmail.com9418130228

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026